The AHA today filed a friend-of-the-court brief supporting the Department of Health and Human Services’ motion to dismiss AbbVie’s lawsuit challenging the agency’s longstanding definition of “patient” under the 340B Drug Pricing Program.

The AHA argued that AbbVie is attempting to bypass the 340B program’s required audit and administrative dispute resolution processes and use litigation to change established program rules. The association said that HHS’ interpretation of “patient” is consistent with the 340B statute and allowing the case to proceed could deprive hospitals of due process protections guaranteed under the law.

Joining the AHA in the brief were America’s Essential Hospitals, the Children’s Hospital Association, the Association of American Medical Colleges and the American Society of Health-System Pharmacists.

Headline
The AHA Aug. 25 submitted comments to Sen. Bill Cassidy, R-La., on the 340B Drug Pricing Integrity and Affordability for Patients Act (340B for Patients Act),…
Headline
A bipartisan group of senators Aug. 5 introduced the Supporting Underserved and Strengthening Transparency, Accountability and Integrity Now and for the Future…
Headline
The Department of Health and Human Services today issued a notice announcing a revised 340B Rebate Model Pilot Program, allowing qualifying drug manufacturers…
Headline
The U.S. District Court for the District of Columbia July 21 upheld a lower court’s decision that Section 340B of the Public Health Service Act does not …
Headline
The AHA July 14 urged the Health Resources and Services Administration to revise its estimate of the administrative burden associated with the agency’s…
Headline
The Health Resources and Services Administration announced that 340B covered entities purchased $100 billion in outpatient drugs under the federal 340B Drug…